Hanhwa veers into biosimilar market
Hanwha is set to conduct Phase I trial of ‘HD203’ (etanercept) under the approval of Korea Food and Drug Administration last month
Etanercept (Enbrel) ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
